Welcome to our dedicated page for Centene Del news (Ticker: CNC), a resource for investors and traders seeking the latest updates and insights on Centene Del stock.
Centene Corporation (NYSE: CNC) news coverage tracks developments from the largest Medicaid managed care organization in the United States. As a Fortune 500 healthcare company managing coverage for tens of millions of Americans through government-sponsored programs, Centene's announcements carry implications for state healthcare policy, Medicare beneficiaries, and the managed care industry.
The company's news flow reflects its diverse operations across Medicaid, Medicare Advantage, and marketplace exchange businesses. Subsidiary announcements from Wellcare regarding Medicare enrollment periods and plan offerings appear regularly, as do updates from regional health plans like Health Net, Meridian, and Ambetter regarding community investments and local market initiatives. State contract awards, renewals, and Medicaid program developments generate coverage given their direct impact on the company's membership and revenue.
Earnings reports reveal segment performance across Centene's government program mix and specialty services businesses. Investor attention focuses on medical cost trends, membership growth, quality ratings, and contract developments. Material events disclosed through SEC filings—including executive changes, litigation developments, and strategic transactions—surface through this news feed alongside company announcements.
Community health initiatives represent a consistent theme in Centene's communications, reflecting the company's focus on social determinants of health. Partnerships addressing food insecurity, housing stability, and healthcare access for underserved populations demonstrate the company's approach to member engagement and state contract requirements. Follow this page for Centene earnings, contract announcements, subsidiary developments, and healthcare policy news affecting managed care organizations.
Investor consortium led by Nautic Partners, The Vistria Group, and General Atlantic has reached a definitive agreement to acquire PANTHERx Rare from Centene Corporation (NYSE: CNC). This strategic move aims to accelerate PANTHERx's growth as a specialty pharmacy for rare and orphan diseases. With a focus on meeting the unique needs of patients, the consortium anticipates leveraging expertise to drive innovation. The transaction awaits clearance under the Hart-Scott Rodino Act and other customary conditions. PANTHERx is recognized for its achievements in the specialty pharmacy sector.
Centene Corporation (NYSE: CNC) announced the sale of two pharmacy businesses, Magellan Rx and PANTHERx, to Prime Therapeutics and a consortium respectively, generating approximately $2.8 billion in proceeds. This move aligns with Centene's strategy to exit the Pharmacy Benefit Management space, enhancing value creation. Magellan Rx, acquired in January 2022, is known for specialty drug management, while PANTHERx, acquired in December 2020, excels in rare pharmacy. The transactions are expected to be neutral to slightly accretive to Centene’s Adjusted Earnings Per Share post-closing.
Centene Corporation (NYSE: CNC) will present at the Bank of America 2022 Healthcare Conference in Las Vegas from May 9-13, 2022. The company's presentation is scheduled for May 10 at 8:40 a.m. PT, with a live audio webcast available at this link. A replay will be accessible on Centene's website under the Investors section afterwards. Centene is a leading healthcare enterprise focused on providing integrated, cost-effective services, particularly for under-insured and uninsured individuals.
Centene Corporation (NYSE: CNC) reported Q1 2022 results showing a diluted EPS of $1.44 and an adjusted diluted EPS of $1.83, with total revenues of $37.2 billion, up 24% year-over-year. Membership rose by 1.9 million to 26.2 million. The health benefits ratio stood at 87.3%, a slight increase from last year. Additionally, the company raised its 2022 revenue and EPS guidance, projecting adjusted EPS between $5.40 to $5.55.
CEO Sarah London emphasized ongoing operational excellence as key to sustainable growth.
On April 21, 2022, Meridian of Michigan highlighted the rising issue of cyberbullying among the youth, emphasizing its negative impacts on mental health. A Pew Research study indicates that 59% of U.S. teens have experienced online harassment. Meridian's Chief Medical Officer, Dr. Kay Judge, notes the challenges this presents for parents and the community. To combat this, Meridian encourages youth participation in the Centene Institute Youth Impact Award for Cyberbullying Prevention, with a submission deadline of May 20, 2022. The initiative aims to promote awareness and prevention strategies.
Centene Corporation's Board of Directors has accepted the resignation of Leslie V. Norwalk as a Board member. The Board expresses appreciation for her service. The company has been enhancing its corporate governance since November 2021 by appointing five new Board members, refreshing committee chairs, separating the CEO and Chairman roles, and appointing a new lead independent director. The Board supports CEO Sarah London and her leadership team in executing the company's value creation strategy.
Meridian Michigan has appointed Dr. Kay Judge as its new Chief Medical Officer, effective April 10, 2022. Dr. Judge brings over 20 years of experience from health systems in Michigan and California, including her role as Regional Medical Director at Health Net, a Centene subsidiary. She is recognized for her work in reducing healthcare disparities and implementing technology to enhance health outcomes. Dr. Judge aims to uphold Meridian's reputation for high-quality managed care. Meridian is a subsidiary of Centene Corp. (NYSE: CNC), serving Medicaid and Medicare-Medicaid populations in Michigan.
Centene Corporation (NYSE: CNC) will host its 2022 Annual Meeting of Stockholders on April 26, 2022, at 11:00 a.m. ET, following the release of its first-quarter financial results. The meeting will be held at Centene's headquarters in St. Louis, Missouri. Attendees can access a live audio webcast via the company's investor relations website. Centene emphasizes its commitment to providing integrated healthcare services, focusing on underserved populations, including Medicaid and Medicare members.
Welsh, Carson, Anderson & Stowe (WCAS) announced the appointment of Jesse Hunter as an Operating Partner in its Healthcare Group. Hunter, a former executive at Centene Corporation (NYSE: CNC), brings over 20 years of leadership experience, particularly in Mergers & Acquisitions and strategic growth. During his tenure at Centene, he played a key role in expanding the company into a $125 billion enterprise focused on government healthcare programs. His addition is expected to enhance WCAS's portfolio in managed care and population health.
Centene Corporation (NYSE: CNC) has appointed Sarah London as Chief Executive Officer, effective immediately, succeeding Michael Neidorff, who is on medical leave. London, previously Vice Chairman, will focus on enhancing integrated, value-based care. Her leadership in technology and corporate strategy is expected to drive innovation within the company. The Board praised her strategic insight and commitment to member care. Centene serves over 26 million Americans, focusing on providing high-quality, affordable healthcare.
FAQ
What is the current stock price of Centene Del (CNC)?
What is the market cap of Centene Del (CNC)?
